Introduction

Diabetic eye disease, particularly diabetic retinopathy (DR) and diabetic macular edema (DME), remains a leading cause of preventable vision loss among working-age adults globally. With over 537 million people living with diabetes worldwide according to the International Diabetes Federation, the prevalence of DR is projected to rise substantially over the coming decade. While current treatments have reduced blindness rates significantly compared with prior decades, they are burdened by frequent injections, incomplete responses, and notable side effects. The emergence of dual therapy—combining mechanistically distinct agents to target multiple pathogenic pathways—represents a pivotal shift toward personalized medicine in ophthalmology. This approach promises more durable outcomes and reduced treatment burden, moving beyond symptom management to address the underlying disease processes driving retinal damage and vision loss.

The Growing Burden of Diabetic Eye Disease

Diabetic retinopathy affects approximately one-third of all diabetic patients, with DME being the most common cause of vision loss in this population. The economic and social impact is enormous: direct healthcare costs for DR management in the United States alone exceed $500 million annually, and the indirect costs from lost productivity, disability, and caregiver burden are even higher. As diabetes rates continue to climb—projected to affect 700 million people by 2045—the urgency for more effective and sustainable therapies has never been greater. Current standard-of-care—intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents—has improved outcomes but remains far from optimal for a substantial subset of patients.

The disease burden extends beyond clinical measures. Patients with DME often experience difficulty reading, driving, and performing daily tasks, leading to reduced quality of life, increased fall risk, and higher rates of depression. The socioeconomic gradient is steep: individuals from lower-income backgrounds often present with more advanced disease, have poorer access to care, and experience worse visual outcomes. This disparity underscores the need for treatments that can achieve durable disease control with fewer visits and injections, thereby improving access and equity.

Epidemiology and Risk Factors

DR progresses through stages: mild nonproliferative DR advances to moderate and severe forms, eventually converting to proliferative DR (PDR) characterized by neovascularization. DME can occur at any stage and is defined by retinal thickening involving the macula. Key risk factors include duration of diabetes, glycemic control as measured by hemoglobin A1c, hypertension, dyslipidemia, and obesity. Pregnancy and puberty can accelerate progression. Importantly, even patients with excellent glycemic control can develop DME, indicating that other drivers—particularly inflammation and neurodegeneration—play independent roles.

Pathophysiology: Beyond VEGF

Chronic hyperglycemia triggers a cascade of metabolic and inflammatory events that damage retinal capillaries, pericytes, and neurons. Capillary occlusion leads to retinal ischemia, which upregulates hypoxia-inducible factors and stimulates VEGF production. However, VEGF is only one of many mediators. Inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and chemokines like MCP-1 also drive vascular leakage and neurodegeneration. This multifactorial pathophysiology explains why single-agent therapies often yield incomplete or transient responses. DME arises from breakdown of the blood-retinal barrier, resulting in fluid accumulation in the macula. While anti-VEGF agents effectively reduce leakage by blocking VEGF-A, they do not address the concurrent inflammatory component or the pericyte loss and neuroglial dysfunction. Consequently, many patients experience persistent edema despite treatment.

The Role of Inflammation

Inflammation is a central, not secondary, driver of DME. Elevated levels of IL-6, MCP-1, ICAM-1, and other inflammatory mediators are found in the vitreous and aqueous humor of patients with DME. These molecules promote leukostasis, which is the adhesion of leukocytes to retinal vascular endothelium, causing capillary occlusion and endothelial damage. Corticosteroids suppress this inflammatory cascade broadly, which is why they remain effective even in anti-VEGF-refractory cases. The inflammatory phenotype—characterized by high cytokine levels, hyperreflective foci on optical coherence tomography (OCT), and significant hard exudates—predicts a favorable response to corticosteroid-based therapy.

Neurodegeneration and Pericyte Loss

DR is also a neurodegenerative disease. Retinal ganglion cell loss occurs early, before clinically detectable vascular changes. This neurodegeneration contributes to visual dysfunction that may not be captured by standard measures of visual acuity. Pericytes—contractile cells that support retinal capillaries—are lost early in DR, leading to microaneurysm formation, capillary dropout, and blood-retinal barrier breakdown. Therapies that address pericyte protection and neuronal survival, such as Tie2 activators, are being investigated as part of dual therapy strategies.

Current Standard Therapies and Their Limitations

Anti-VEGF monotherapy (ranibizumab, aflibercept, bevacizumab) is the first-line treatment for DME, with numerous randomized trials demonstrating efficacy in reducing central retinal thickness and improving visual acuity. However, up to 40% of patients show suboptimal anatomical or functional improvement. Frequent injections every 4–8 weeks are required, imposing a high burden on patients and healthcare systems. Long-term adherence is challenging—studies show that many patients miss scheduled doses, leading to rebound edema and worse outcomes. Cumulative risks include endophthalmitis, retinal detachment, cataract formation, and intraocular inflammation. Moreover, some patients develop tachyphylaxis—a gradual loss of efficacy over time—necessitating a switch in therapy or the addition of a second agent.

Corticosteroids, such as dexamethasone and fluocinolone acetonide implants, offer an alternative by suppressing multiple inflammatory pathways. They are particularly useful in patients who are refractory to anti-VEGF or have a significant inflammatory component. However, corticosteroid use is limited by cataract progression (nearly universal after one year with the dexamethasone implant) and steroid-induced ocular hypertension, which requires vigilant monitoring and often additional interventions such as glaucoma drops or surgery. Laser photocoagulation, once the mainstay, has largely been supplanted by pharmacotherapy for DME, though it remains valuable for proliferative DR and for treating peripheral retinal ischemia. Its destructive nature and inability to improve vision limit its role in macular disease.

These limitations underscore the need for therapies that can achieve more profound and sustained disease control while reducing the frequency of interventions. Dual therapy, by targeting both VEGF-driven angiogenic pathways and broader inflammatory cascades, offers a rational and increasingly well-supported solution.

The Rationale for Dual Therapy

Dual therapy in diabetic eye disease involves the concurrent use of two agents with complementary mechanisms of action. The most extensively studied combination is anti-VEGF plus corticosteroid, but newer combinations—such as anti-VEGF plus anti-placental growth factor (PlGF), anti-VEGF plus Tie2 activators, or bispecific antibodies—are under active investigation. The theoretical advantages are compelling: enhanced efficacy through blockade of multiple pathogenic cascades, longer duration of action, potential for fewer injections, and improved preservation of retinal architecture and function.

Mechanisms of Synergy

Anti-VEGF agents neutralize VEGF-A, reducing vascular leakage and neovascularization. Corticosteroids inhibit phospholipase A2, reduce prostaglandin synthesis, and suppress expression of cytokines, chemokines, and adhesion molecules. By combining these agents, clinicians can simultaneously interrupt the VEGF-driven vascular component and the broader inflammatory milieu. Preclinical studies show that combination therapy leads to greater reduction in vascular permeability and leukostasis compared to either agent alone. Clinical data from randomized trials suggest that the combination can achieve superior anatomical outcomes, especially in patients with high inflammatory burden as evidenced by hyperreflective foci on OCT or high vitreous cytokine levels.

Bispecific Antibodies and Dual-Action Molecules

The most advanced example is faricimab, a bispecific antibody that binds both VEGF-A and angiopoietin-2 (Ang-2). Ang-2 promotes vascular permeability and destabilizes pericytes, working synergistically with VEGF. Phase 3 trials (YOSEMITE, RHINE) demonstrated that faricimab given every 8–16 weeks was non-inferior to aflibercept dosed every 8 weeks, with a significant proportion of patients achieving extended dosing intervals beyond 12 weeks. This represents a major step toward personalized medicine, as a single drug targets two pathways with less frequent injections. Other emerging strategies include anti-VEGF plus anti-PlGF combinations, which may reduce fibrosis and neovascularization more effectively than anti-VEGF alone, and integrin inhibitors that disrupt endothelial cell adhesion to the extracellular matrix.

The Role of Tie2 Activation

The angiopoietin-Tie2 pathway is a critical regulator of vascular stability. Ang-1 binding to Tie2 promotes pericyte coverage, reduces vascular permeability, and suppresses inflammation. Ang-2 acts as a competitive antagonist, destabilizing the vasculature. Faricimab neutralizes Ang-2, thereby restoring Tie2 signaling and stabilizing the retinal vasculature. This dual blockade of VEGF and Ang-2 provides a more comprehensive approach than VEGF inhibition alone and explains the extended durability seen in clinical trials. Other Tie2-activating approaches, such as AKB-9778 (a Tie2 activator), are also being studied in combination with anti-VEGF.

Personalized Medicine and Biomarker-Guided Therapy

Personalized medicine aims to select the right treatment for the right patient at the right time. In diabetic eye disease, this requires identifying biomarkers that predict response and disease progression. Genetic polymorphisms in the VEGF gene have been associated with variable responses to anti-VEGF therapy. For instance, patients with certain VEGF haplotypes may require higher doses or more frequent injections to achieve adequate VEGF blockade. Vitreous and serum levels of inflammatory cytokines (IL-6, MCP-1) can identify an "inflammatory phenotype" that may benefit from corticosteroid-based therapy. Advanced imaging, such as OCT and OCT angiography (OCTA), can quantify capillary non-perfusion, intraretinal fluid, and hyperreflective foci that correlate with disease activity and treatment response.

Imaging Biomarkers

OCT biomarkers that predict response to dual therapy include disorganization of retinal inner layers (DRIL), the presence of hyperreflective foci (which correlate with lipid-laden macrophages and inflammatory activity), and the integrity of the ellipsoid zone. Patients with significant DRIL and hyperreflective foci at baseline are more likely to benefit from combined anti-VEGF and corticosteroid therapy. OCTA can assess capillary density and identify areas of non-perfusion that may drive chronic VEGF production. The foveal avascular zone (FAZ) area on OCTA is a biomarker of disease severity and may predict poor visual recovery. Machine learning algorithms are being integrated to analyze these multimodal imaging data alongside clinical parameters, enabling more accurate patient stratification and treatment selection.

Incorporating Machine Learning

Artificial intelligence models are being trained on large datasets of OCT images and clinical outcomes to predict which patients will respond best to which therapy. For example, deep learning algorithms can identify patterns of intraretinal fluid, subretinal fluid, and hyperreflective foci that correlate with a favorable response to corticosteroid-containing regimens. These tools have the potential to guide clinical decision-making in real time, helping clinicians choose between anti-VEGF monotherapy, dual therapy, or corticosteroid monotherapy based on the individual patient's disease phenotype. As these models are validated and integrated into electronic health records, they will become indispensable for precision ophthalmology.

Clinical Evidence for Dual Therapy

Several clinical trials have evaluated dual therapy in DME. The BEVORDEX trial compared combination of bevacizumab and dexamethasone implant versus ranibizumab monotherapy. Over 24 months, the combination group achieved comparable visual outcomes with significantly fewer injections, though cataract surgery rates were higher. The study highlighted that dual therapy can reduce treatment frequency, which is a substantial advantage for patient compliance and healthcare resource utilization. Other trials, such as the combination of aflibercept and dexamethasone implant, have shown improved anatomical outcomes in patients with persistent DME despite prior anti-VEGF therapy.

The BOOST trial investigated suprachoroidal delivery of triamcinolone acetonide combined with intravitreal anti-VEGF, demonstrating promising anatomical improvements with reduced systemic exposure compared to intravitreal corticosteroid delivery. This delivery method may minimize corticosteroid-related side effects such as glaucoma, as the drug is delivered directly to the chorioretina with less access to the anterior segment. Real-world evidence from large registries is accumulating, showing that dual therapy is increasingly used in clinical practice for refractory DME. However, prospective randomized data are still needed to define optimal patient selection, dosing regimens, and sequencing strategies.

Faricimab in Clinical Practice

Faricimab has been approved for DME and neovascular age-related macular degeneration based on the YOSEMITE and RHINE trials. In these studies, faricimab 6 mg administered every 8 weeks or according to a personalized treat-and-extend protocol was non-inferior to aflibercept 2 mg every 8 weeks, with a higher proportion of faricimab-treated patients achieving 16-week dosing intervals. This extended durability represents a meaningful reduction in treatment burden. Real-world studies are now confirming these findings and exploring how faricimab performs in patients with a high inflammatory burden who may have been suboptimal responders to prior anti-VEGF therapy.

Ongoing Research and Future Directions

Several phase 2 and 3 trials are exploring new dual-acting therapies. For instance, combined anti-VEGF and anti-PlGF agents aim to reduce fibrosis and improve outcomes in proliferative DR. Port delivery systems for anti-VEGF, which allow refillable implants that can be refilled every 6–9 months, are being combined with corticosteroid implants to provide extended coverage for patients with chronic DME. Furthermore, oral agents targeting inflammation, such as PDE4 inhibitors, are being investigated as systemic adjuncts for bilateral disease. Adaptive trial designs that adjust treatment based on real-time biomarker responses—for example, escalating to dual therapy only in patients who show an incomplete response to monotherapy after 4 weeks—will likely become more common, bringing personalized medicine closer to clinical reality.

Challenges and Considerations

Despite its promise, dual therapy faces several hurdles. Adding a second agent increases regimen complexity, particularly when both are injectable. The logistical burden, potential for drug-drug interactions, and higher costs must be justified by improved outcomes. Corticosteroid use requires careful monitoring of intraocular pressure and cataract formation; some patients may need surgical intervention for cataracts or glaucoma. Not all patients require dual therapy—overtreatment can expose them to unnecessary risks and costs. Hence, biomarker-driven patient selection is essential to maximize benefit-risk ratio.

Cost and Access

Equitable access is a critical concern. Advanced therapies like faricimab and sustained-release corticosteroid implants are expensive, with annual costs that can exceed $10,000 per patient. Healthcare systems must develop policies to ensure that underserved populations are not excluded from these innovations. This includes negotiating drug pricing, developing alternative payment models, and investing in telemedicine and community-based care to reduce geographic and economic barriers. Patient education about the rationale and expectations of dual therapy is crucial for adherence and shared decision-making.

Monitoring and Safety

Patients receiving corticosteroid-based dual therapy require regular intraocular pressure monitoring, typically at every visit. Cataract formation is accelerated with corticosteroids, and many patients will require cataract surgery within 1–2 years of initiating therapy. The risk of endophthalmitis and retinal detachment increases with each injection, so minimizing injection frequency is a key goal. Real-world evidence from post-marketing studies and registries will help refine protocols, identify optimal candidates, and detect rare adverse events that may not emerge in clinical trials. Comparative effectiveness research against current standards will guide clinical decision-making and reimbursement policies.

Conclusion

The future of diabetic eye disease management lies in personalized medicine powered by dual therapy. By targeting multiple pathogenic pathways simultaneously—whether through combined drugs, bispecific molecules, or implantable devices—clinicians can achieve better visual outcomes, reduce treatment burden, and preserve vision longer. Biomarkers and advanced imaging will enable precise patient stratification, ensuring that the right patients receive the right combination at the right time. Continued investment in translational research, clinical trials, and healthcare infrastructure is essential to realize this vision. The ultimate goal is to preserve sight and improve quality of life for the hundreds of millions of individuals affected by diabetes worldwide, reducing disparities and ensuring that innovation reaches those who need it most.

For further reading: American Academy of Ophthalmology – Preferred Practice Patterns for Diabetic Retinopathy. National Eye Institute – Facts About Diabetic Eye Disease. PubMed – Review of dual therapy in diabetic macular edema. Diabetes Care – Management of Diabetic Retinopathy. PMC – Faricimab and the Ang-2/VEGF pathway.